Went public 11/14/00 at $15 per share
Filing Range:6.0 million shares @ $15 to $17
Shares Outstanding:26.849 million shares
Underwriters: Merrill Lynch & Co./Lehman Brothers/Pacific Growth Equities Inc.
Company Counsel: Dechert Price & Rhoads
Manager Counsel: Brobeck Phleger & Harrison LLP
Auditor: KPMG LLP
Develops biopharmaceuticals, including novel analgesics and products for pain management. The company develops next-generation centrally and peripherally-acting, non-addictive analgesics for the treatment of hyperalgesia (inflammatory pain), pruritis (itch), mild-moderate and moderate-severe pain. The company is also developing products that are designed to greatly diminish most of the prevalent and dose-limiting side effects of current narcotic therapy.
Lightspeed Venture Partners
ARCH Venture Partners
OrbiMed Advisors LLC
HarbourVest Partners LLC.
Burr Egan Deleage & Co.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 11/01/1994 3 Early Stage 1500.0
2 06/01/1996 6 Early Stage 7547.0
3 05/02/1997 9 Expansion 9670.0
4 12/08/1998 9 Later Stage 8525.0
5 01/28/2000 12 Expansion 12300.0
6 07/10/2000 10 Later Stage 35883.0
(Data in $ millions)
Total Revenues: 0.0
Net Income: -10.1